Skip to Content

First Trust Nasdaq Pharmaceuticals ETF FTXH

Medalist Rating as of | See First Trust Investment Hub

Morningstar’s Analysis FTXH

Will FTXH outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

The combination of an Average People Pillar rating and a Below Average Process Pillar rating limit First Trust Nasdaq Pharmaceuticals ETF to a Morningstar Medalist Rating of Negative.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a sizable cost advantage over competitors, priced within the least expensive fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings FTXH

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 54.2
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Pfizer Inc

7.43 1.5 Mil
Healthcare

Bristol-Myers Squibb Co

7.41 1.5 Mil
Healthcare

AbbVie Inc

7.28 1.5 Mil
Healthcare

Merck & Co Inc

7.06 1.5 Mil
Healthcare

Johnson & Johnson

6.91 1.4 Mil
Healthcare

Amgen Inc

3.68 763,597
Healthcare

Eli Lilly and Co

3.68 763,276
Healthcare

Gilead Sciences Inc

3.59 745,244
Healthcare

Regeneron Pharmaceuticals Inc

3.57 740,006
Healthcare

Cardinal Health Inc

3.57 739,573
Healthcare